Media Hub

View the latest content on Obesity & NASH Drug Development and other events of the CVRM & Liver Series

Obesity & NASH Speaker Interview

An exclusive Interview with: 

Ginnie Yang, Vice President of Inflammation, Exploratory Pathobiology & Tissue Repair, Bayer

NASH Summit FDA Presentation First Page

An exclusive FDA presentation by:

Dr Frank A. Anania, Acting Clinical Team Leader, Division of Gastroenterology and Inborn Error Products, FDA

future of nash

Laurent Fischer, MD Senior Vice President, Liver Therapeutic Area Head, ALLERGAN PLC


Capturedefef resized

Peter G. Traber, MD Partner, Alacrita Consulting : NASH Now: Therapeutic Targets & the Competitive Clinical Trial Landscape


Brent A. Neuschwander-Tetri, Professor of Internal Medicine - Saint Louis University. : Many Paths to NASH- Many Targets for Treatment


Yury Popov, MD PhD, Beth Israel Deaconess Medical Center, Harvard Medical School: Understanding Hepatocellular Carcinoma as an Extension of NASH: practical implications for drug development


Liat Hayardeny, Chief Scientific Officer, Galmed Pharmaceuticals: Aramchol Phase II b Results & Phase III Outlook


Greg Everson, Chief Executive Officer & Manager, HepQuant: Tests of the Liver’s Function and Physiology to Assess Liver Disease and Monitor Treatment Effects


Nikolai Naoumov, MD PhD, Exucutive Director - Hepatology Science& Innovation, Global Drug Development Novartis Pharma: Which Mechanisms of Action to Combine to Address NASH


Eric Lefebvre, Chief Medical Officer - Pliant Therapeutics Inc. : Disruption of TGF β activation by an α V β 1 integrin inhibitor reduces liver fibrosis in human NASH liver slices and mice

Targeting multiple pathways in NASH - clinical perspectives for combination therapies | Nikolai Naoumov

Molecular MR Imaging of Oxidized Collagen to Monitor Active Fibrogenesis in Preclinical Models of NASH | Bryan Fuchs

Targeting multiple pathways
Molecular MR Imaging

Evaluating Progression Towards Industry Standard In Vitro Models of NAFLD/NASH

In Vitro